本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
SEOUL, South Korea, Dec. 31, 2024 /PRNewswire/ -- CG MedTech (f/k/a Innosys, CEO Ju Mi Chung), a leading Korean orthopedic implant research and manufacturing company, partnered with CGBIO to host the International Spine Endoscopy Training Course. The event welcomed 12 medical professionals from nine countries, including Mexico, Switzerland, and India. Led by Professor Jin-Sung Kim (also known as Luke) of Seoul St. Mary's Hospital, The Catholic University of Korea — a world-renowned expert in minimally invasive and endoscopic spine surgery — the program showcased Korea's leadership in advanced surgical techniques and medical device innovation. CG MedTech and CGBIO Showcase Korea’s Spine Surgery Excellence to Global Experts The training course featured advanced spine model simulators from Germany, Canada, and Italy. These simulators replicated human anatomical structures, including blood vessels, muscles, bones, and ligaments, providing participants with an unparalleled hands-on experience. The program focused on full-endoscopic and biportal endoscopic spine surgery, a minimally invasive technique that reduces recovery time and complications while enabling precise, multi-angle access. The involvement of global simulator manufacturers highlights the growing recognition of Korea's expertise in spine surgery.Participants engaged in practical sessions led by Professors Jin-Sung Kim, Sang Hyun Han, and Jung Hoon Kim, which featured cutting-edge Korean medical devices. These included CG MedTech's Anax MIS System, designed for precise pedicle screw placement with minimal tissue disruption, and CGBIO's NOVOSIS, a bone substitute celebrated for its biocompatibility and effectiveness. Also showcased were CGDERM Spinkle, an anti-adhesion agent enhancing surgical safety, and the Excender expandable cage, praised for its innovative design that restores disc height and angle, even in challenging surgical environments."CG MedTech, with CGBIO, is committed to advancing global medical education by sharing innovative surgical methods and premium devices," said Ju Mi Chung, CEO of CG MedTech. "Our mission is to enhance the skills of medical professionals worldwide while strengthening Korea's leadership in this field."The event, hosted by the Catholic University of Korea (International Skills Center), received support from the Ministry of Health and Welfare and the Korea Health Industry Development Institute. The Regional Domestic Medical Device Education and Training Support Center—Korea's first comprehensive training hub for medical devices—played a vital role in bridging government initiatives with industry collaboration.Programs like this firmly establish Korea as a global hub for advanced medical technology and education. The collaboration between CG MedTech, CGBIO, and international institutions reaffirms Korea's commitment to innovation and its leadership in spine surgery education and technology. CG MedTech and CGBIO Showcase Korea’s Spine Surgery Excellence to Global Experts
TEL AVIV, Israel, Nov. 18, 2024 /PRNewswire/ -- SoniVie Ltd., a medical device company developing a proprietary renal denervation system to treat hypertension, announced today the appointment of Raymond W. Cohen to serve as its chairman of the board of directors. Mr. Cohen has served as the chief executive officer and member of the board of directors of Axonics, Inc., an Irvine, Calif. based global medical technology company he cofounded in 2013 and took public October 31, 2018. Axonics ranked No. 1 on the 2021 Deloitte Technology Fast 500™ and the 2022 Financial Times ranking of the fastest growing companies in the Americas. Cohen is retiring from Axonics following the close of its $3.7 billion sale to Boston Scientific Corporation (NYSE: BSX). Prior to Axonics, Cohen was the CEO of Vessix Vascular, Inc. (privately held) which developed a catheter based renal denervation system that was acquired by BSX in late 2012. Tomaso Zambelli, CEO of SoniVie, said "We look forward to benefiting from Mr. Cohen's broad experience in growing Medtech companies and moreover his expertise in renal denervation as we execute our PMA study for US FDA approval and make plans to commercialize our product." About Raymond W. Cohen An accredited public company director with over 40 years of experience in the life sciences industry, Cohen also serves as an independent director of Kestra Medical Technologies, Inc., (privately held) a commercial stage company manufacturing and marketing a wearable defibrillator product for patients at temporary risk of cardiac arrest. Cohen recently received the 2024 MedTech MVP Award and was also named Businessperson of the Year by the Orange County Business Journal. In 2021, Mr. Cohen received a lifetime achievement award from SoCal Bio for his four decades of work in medical technology. In late 2020, Mr. Cohen was named as Entrepreneur of the Year by Ernst & Young for the Pacific Southwest United States. About SoniVie Ltd. SoniVie has developed TIVUS™ (Therapeutic Intra-Vascular Ultrasound System) which employs high-frequency non-focused ultrasound energy to ablate nerves in the renal artery to decrease blood pressure for patients suffering from hypertension, a condition impacting millions of people worldwide and substantially increasing their risk of heart attack, stroke and kidney failure. In July 2024, the United States FDA approved the company's PMA study which is now enrolling patients in the US, Europe and Israel. The "THRIVE" study is an international, multicenter, randomized, double blind, sham-controlled study, designed to demonstrate the safety and effectiveness of the TIVUS™ System in hypertensive subjects who are off anti-hypertensive medications one month prior to the procedure until 2 months post procedure. Unblinding will be performed 6 months post procedure. SoniVie has operations in Israel, US and Europe. For more information, please go to www.sonivie.com PR Contact: Tomaso Zambelli, CEOSonivie Ltd.tomaso@sonivie.com
SHENZHEN, China, Oct. 13, 2024 /PRNewswire/ -- The 90th China International Medical Equipment Fair (CMEF) has successfully kicked off in Shenzhen, running from October 12-15. This year's event spans nearly 200,000 square meters and hosts nearly 4,000 exhibitors with an audience surpassing 200,000 from over 130 countries. During the opening ceremony, Reed Sinopharm Exhibitions (RSE) and the Association of Private Hospitals of Malaysia (APHM) signed a strategic partnership agreement aimed at shaping the future of medical development in Malaysia. The CMEF continues to be the leading global platform integrating the entire medical device industry chain. It features product technology showcases, brand promotions, trade opportunities, and academic forums. Numerous groundbreaking products are unveiled at this year's CMEF, some of which include: Endoscope Anti-Fog Solution: China National Medical Device (CMDC) unveiled their V301 - a state-of-the-art endoscopic camera system featuring advanced defogging technology. During procedures, pressing a button on the handle quickly restores a clear image within 5-10 seconds. All-Digital Brain PET System: Raysolution showcased their DigitMI i30 - a fully digital PET scanner for brain imaging boasting unmatched resolution and sensitivity. This product employs the multi-voltage threshold (MVT) digitization, achieving a spatial resolution of 1.0mm, a time of flight of 249ps, and a sensitivity of 30 kcps/MBq. Innovative Medical Robotics: Chunli Medical showcased their newest handheld orthopedic robotics designed for hip and knee joints, featuring innovative integration of advanced sensor control and autonomous perception systems. Portable Ultrasound System: Dawei Medical showcased their groundbreaking handheld ultrasound, providing users with a wireless vision at their fingertips. Simple Respirator: Lanswick featured their patented Simple Respirator, offering real-time visualization of artificial ventilation, monitoring lung compliance and airway resistance for precise ventilation control. Sustainable Cabin for Medical Waste: Beijing Aerorate Protection presented their new medical waste disposal cabin that offers eco-friendly on-site treatment solutions. This innovative approach eliminates the potential for secondary pollution during waste transportation and introduces a fresh disposal method for hospital complexes and remote regions. A notable feature of this year's exhibition is a strategic agreement. In June 2025, RSE will host THE HEALTH INDUSTRY SERIES – ASEAN (tHIS ASEAN) co-located with APHM. The Southeast Asian healthcare market is set for rapid expansion, with an expected annual growth rate of 10-12%. This partnership seeks to unite healthcare professionals and industry leaders in Southeast Asia, encouraging cooperation and progress to improve global health standards. In addition, over sixty high-end conferences and forums are taking place at CMEF, with more than 1000 industry leaders exploring critical insights into healthcare advancements. Notable sessions on the WeTalk Global Stage include UK-GBA Life Sciences Business Matching, Israeli Medical Equipment Roadshow. The 90th CMEF also offers business matchmaking services at the Distributor Alliance Club, drawing thousands of distributors globally. The ongoing success of CMEF underscores its status as the premier gateway for foreign brands entering China's market while highlighting its pivotal role in driving forward global healthcare innovations. The 91st CMEF will be held on April 8-11 in Shanghai, please stay tuned! For more information: www.cmef.com.cn/en
Clarivate Medtech Intelligence and Relatable software enhance product data management and competitive conversion efficiency for medtech sales, contracting and pricing teams LONDON, Sept. 23, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced a strategic partnership with Relatable Healthcare, a technology company delivering Product Relationship Management (PRM) software to leading medtech companies to drive revenue and workflow efficiency. Relatable™ is a Product Relationship Management (PRM) platform created for medtech manufacturers and distributors to unlock new competitive conversion capabilities that drive cost-efficient revenue growth. The platform establishes a single source of truth for all information associated with specific products and their direct competitors, populating a data management platform available to contracting, sales, marketing and technical support teams. Within the Relatable™ platform, customers can now access comprehensive competitive intelligence from Clarivate in addition to product specifications and cross-references, inventory availability, sales collateral, EPP data, chemicals of concern, manufacturing origin, or any custom proprietary data a customer wishes to manage. This partnership empowers Clarivate and Relatable clients to make confident strategic pricing decisions, streamline sales contracting processes, and enhance contract compliance by offering comprehensive tools and insights to manage the entire contracting cycle effectively. Andrew Lee, Vice President Medtech, Life Sciences & Healthcare, Clarivate, said: "At Clarivate, we are focused on expanding our market intelligence and data analytics offering in the medical device and technology sectors while providing powerful workflow solutions that turn data-driven insights into decisions and actions that accelerate growth for our clients. This new strategic partnership enables us to support the industry in getting products to patients faster." Joshua Emert, CEO of Relatable Healthcare, said: "At Relatable Healthcare, we are dedicated to creating intuitive software that modernizes how innovative medical device and supply companies leverage product intelligence to drive efficient revenue growth. We are excited to partner with Clarivate and its medtech customers to automate workflows across contracting, sales, marketing and product support. This will enable instant cross-referencing of competitive products in RFP responses, more frequent measurement of contract compliance and proactive discovery of conversion opportunities in the field." In an evolving healthcare landscape, medical device and supply companies, along with their distributors, face significant challenges in communicating their product value and offering consultative insights. They also struggle with driving adoption and analyzing market trends effectively. Cost-constrained healthcare providers rigorously evaluate purchasing decisions, comparing devices and supplies in detail. To meet this demand, medtech companies require up-to-date competitive intelligence and advanced software to analyze and communicate tailored portfolio insights for each contracting, sales and conversion opportunity. This collaboration enables medtech companies to commercialize products and serve Integrated Delivery Networks (IDNs), Group Purchasing Organizations (GPOs), health systems and independent hospitals, surgery centers and clinics, streamlining the entire revenue growth process more efficiently. Combining the deep product-level market knowledge of Clarivate with enterprise software by Relatable Healthcare equips medtech companies with the insights and tools to win new business and drive contract compliance. About Clarivate Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com About Relatable Healthcare Relatable Healthcare is a technology company delivering pioneering Product Relationship Management (PRM) solutions for the medical device and supply industry. Our data management tools and automated workflows help leading MedTech organizations drive efficient revenue growth across the commercialization spectrum. For more information, please visit www.relatable.io Media Contact:Luna Ivkovic,External Communications, Life Sciences & Healthcarenewsroom@clarivate.com
SINGAPORE, Aug. 19, 2024 /PRNewswire/ -- Genesis MedTech has sold JC Medical, Inc. to Edwards Lifesciences, including the intellectual property and commercial rights of its J-Valve® System, a transcatheter aortic valve replacement for the treatment of severe aortic regurgitation. The transaction includes an upfront payment plus potential sales-based contingent milestones. Genesis MedTech has maintained the exclusive right to develop, manufacture and commercialize the J-Valve® Systemin in Greater China. In July 2023, Genesis MedTech successfully completed patient enrollment for clinical study of J-Valve transfemoral system for the treatment of aortic regurgitation (referred to as J-Valve® TF) in China, and recently concluded the one-year patient follow-up. In August 2023, JC Medical's J-Valve® TF was granted the "Breakthrough Device Designation" by the U.S. Food and Drug Administration (FDA). JC Medical completed enrollment in its early feasibility study (EFS) of J-Valve® TF in the United States in February 2024. Approval from FDA for JC Medical to initiate its pivotal clinical trial of J-Valve® TF was received in the first half of 2024. Additionally, Edwards has made an equity investment of $25 million in Genesis MedTech. This investment will support Genesis MedTech's product and market development efforts, showcasing the recognition of Genesis MedTech's product development capabilities and operational model by a global MedTech leader. "J-VALVE® has unique advantages in treating aortic valve regurgitation." said Warren Wang, Chairman and CEO of Genesis MedTech Group. "We hope that J-Valve® can expand its global impact, enabling more patients to benefit from this innovative product. We will continue strengthening our focus on developing innovative products and explore better medical solutions to benefit more patients worldwide."
SINGAPORE, July 29, 2024 /PRNewswire/ -- APACMed is thrilled to announce that Nobel Laureate and global icon Malala Yousafzai will take centre stage at this year's MedTech Forum, taking place on September 5th and 6th at the Suntec Convention Centre. This highly anticipated event focuses squarely on Artificial Intelligence (AI) and how it's revolutionising the entire healthcare landscape. Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/9281351-malala-yousafzai-apacmed-singapore-medtech/ Malala Yousafzai - Global Icon Malala Yousafzai, renowned for her courageous advocacy for education and women's rights, will join an impressive lineup of game changers, including Tom Lawry (unconventional thought leader), Matthew Luhn (master storyteller), Dr Brent James (healthcare systems innovator) and Associate Professor Tam C. Nguyen (AI research specialist). This global lineup of speakers will address how AI is future-proofing healthcare, transitioning from digital to intelligent systems that promise more personalised and effective patient care. Matthew Luhn - Master Story Teller Dr. Brent James - Healthcare Systems Innovator Tom Lawry - Unconventional Thought Leader "To celebrate our 10th Anniversary, we wanted our forum to be truly innovative," said Harjit Gill, APACMed CEO. "Patient outcomes are affected by many factors - mental, physical and social - which is why we're bringing together different perspectives from a diverse braintrust of speakers. It's more holistic and very much in tune with the 'whole person approach' to the patient journey in a new era of intelligent healthcare." Key features of this year's MedTech Forum include: Dialogue Dens: Themed discussions that dive deep into the role of AI in transforming healthcare, providing a platform for sharing best practices and innovative ideas. Marketplace: A showcase of cutting-edge technologies and solutions from leading innovators, giving attendees firsthand access to the latest advancements in healthcare technology. This year's forum is set to be a milestone event, offering unprecedented opportunities for learning, networking, and exploring how AI can unlock new frontiers in healthcare. With Malala Yousafzai joining the ranks of distinguished speakers, the event is poised to inspire and challenge attendees to envision a future where intelligent healthcare systems drive significant improvements in patient outcomes. For more information on the APACMed MedTech Forum, including registration details and the full agenda, please visit medtechforum.asia #MedTechForumAsia, #GameChangers, #FutureProofingHealthcare, #AI- HealthcareRevolution MedTech Forum 2023 MedTech Forum 2023 - Lance Little, Head of Region, Roche | Harjit Gill, CEO APACMed | John Collings, Chairman APACMed About APACMed and APACMed's MedTech Forum APACMed (Asia Pacific Medical Technology Association) is the leading industry association representing the medical technology industry in the Asia-Pacific region. Our mission is to advance the quality and access of healthcare through innovation and collaboration, driving the adoption of cutting-edge technologies to improve patient outcomes. MedTech Forum is the largest health and medical technology industry conference in Asia-Pacific and a key event since 2014. For sponsorship and other enquiries please contact info@wom.earth
A12 藝術空間
MedTech
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
